Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Improving T2DM outcomes by revising current clinical approaches – Expert review of ADA/EASD Guidelines

Questionnaire

To access this module, please register or login:

Login or Register

Improving T2DM outcomes by revising current clinical approaches – Expert review of ADA/EASD Guidelines
Improving T2DM outcomes by revising current clinical approaches – Expert review of ADA/EASD Guidelines

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please read/watch the module carefully and try once more!
(Only two tries are allowed)
Please note you will no longer receive a fail confirmation email.
Congratulations on successfully completing this FREE CPD module!
- For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile
- For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.
Please note you will no longer receive a pass confirmation email. Your activity automatically downloads on to your deNovo Medica profile.
Visit your profile HERE to find all your CPD certificates and activities completed.

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10
1. Question
1. Heart failure has a prevalence rate among diabetic individuals of:
A. 15%
Correct Incorrect Correct answer

B. 22%
Correct Incorrect Correct answer

C. 32%
Correct Incorrect Correct answer
Question 2 of 10
2. Question
2. In the view of the ESC, type 2 diabetic patients at high CV risk should be treated from the outset of the cardiologists care with either:
A. Metformin monotherapy or a SGLP-2 inhibitor
Correct Incorrect Correct answer

B. Metformin monotherapy or a GLP-1 RA
Correct Incorrect Correct answer

C. Intensified metformin therapy to maximum tolerated dose then add other oral medications
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

E. A and B
Correct Incorrect Correct answer
Question 3 of 10
3. Question
3. The relative risk of treatment failure in the VERIFY trial was reduced by combination therapy by:
A. 29%
Correct Incorrect Correct answer

B. 35%
Correct Incorrect Correct answer

C. 49%
Correct Incorrect Correct answer
Question 4 of 10
4. Question
4. The rates of discontinued therapy of injectable GLP- RA’s is generally about 25%.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 5 of 10
5. Question
5. After 6 months of therapy with either once-weekly exenatide or once-weekly liraglutide as injectables, the proportion of patients with more than 80% of days covered (PDC) was:
A. 1 in 2
Correct Incorrect Correct answer

B. 1 in 3
Correct Incorrect Correct answer

C. 1 in 4
Correct Incorrect Correct answer
Question 6 of 10
6. Question
6. Which of these statements are INCORRECT? In terms of the introduction of insulin in T2DM, the ADA/EASD advise:
A. That patients not on a GLP- RA should be put on this agent
Correct Incorrect Correct answer

B. That the clinician should consider the use of combination products of basal insulin/GLP-1 RA
Correct Incorrect Correct answer

C. That basal-insulin should be preferred to pre-mixed insulin
Correct Incorrect Correct answer

D. That metformin should be stopped when basal-bolus insulin is introduced
Correct Incorrect Correct answer
Question 7 of 10
7. Question
7. In the Lixilan-G study, the modified intention to treat analysis showed that IGlarLixi improved HbA1c levels regardless of whether the patient was on a QD/BID or QW dosage of the GLP-1 RA.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 8 of 10
8. Question
8. IGlarLixi improved HbA1c levels by:
A. 1%
Correct Incorrect Correct answer

B. 1.5%
Correct Incorrect Correct answer

C. 1-1.5%
Correct Incorrect Correct answer
Question 9 of 10
9. Question
9. The baseline level of patients in the IGlarLixi study was:
A. 7.8%
Correct Incorrect Correct answer

B. 9%
Correct Incorrect Correct answer

C. 10%
Correct Incorrect Correct answer
Question 10 of 10
10. Question
10. When comparing IGlarLixi to once-daily or twice-daily GLP-1 RA, as in the Lixilan-G study, the difference in the improvement of HbA1c was:
A. 0.4% better with IGlarLixi
Correct Incorrect Correct answer

B. 0.6% better with IGlarLixi
Correct Incorrect Correct answer

All Rights Reserved 2026 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?